Retension PharmaceuticalsFinal pricing
Retension Pharmaceuticals prices its IPO
Retension Pharmaceuticals prices its IPO (October 8, 2026).
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing medicines for hypertension and other cardiovascular diseases. Its candidate RTN-001 is a once-daily oral PDE-5 inhibitor designed to reduce blood pressure.
Offering details
- Offer price
- $12.0
- Shares offered
- 3.8M
- Exchange
- Nasdaq Capital Market
- Proposed ticker
- RTSN
- Offering size
- $45M